We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market
Read MoreHide Full Article
In the latest trading session, Aquestive Therapeutics (AQST - Free Report) closed at $2.51, marking a -1.95% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.07% for the day.
Heading into today, shares of the specialty pharmaceutical company had gained 23.08% over the past month, outpacing the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98% in that time.
The upcoming earnings release of Aquestive Therapeutics will be of great interest to investors. In that report, analysts expect Aquestive Therapeutics to post earnings of -$0.08 per share. This would mark year-over-year growth of 65.22%. Meanwhile, our latest consensus estimate is calling for revenue of $11.79 million, up 10.36% from the prior-year quarter.
Investors should also take note of any recent adjustments to analyst estimates for Aquestive Therapeutics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Aquestive Therapeutics possesses a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 63, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market
In the latest trading session, Aquestive Therapeutics (AQST - Free Report) closed at $2.51, marking a -1.95% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.07% for the day.
Heading into today, shares of the specialty pharmaceutical company had gained 23.08% over the past month, outpacing the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98% in that time.
The upcoming earnings release of Aquestive Therapeutics will be of great interest to investors. In that report, analysts expect Aquestive Therapeutics to post earnings of -$0.08 per share. This would mark year-over-year growth of 65.22%. Meanwhile, our latest consensus estimate is calling for revenue of $11.79 million, up 10.36% from the prior-year quarter.
Investors should also take note of any recent adjustments to analyst estimates for Aquestive Therapeutics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Aquestive Therapeutics possesses a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 63, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.